Hiroshima University Researchers Develop New Diagnostic Framework to Decode Genetic Variants of Uncertain Significance in Cancer Patients

Hiroshima University researchers debut a diagnostic model to identify hidden pathogenic variants, improving the accuracy of precision oncology and cancer care.

By: AXL Media

Published: Apr 1, 2026, 10:10 AM EDT

Source: Information for this report was sourced from Hiroshima University

Bridging the Diagnostic Gap in Comprehensive Genomic Profiling

While comprehensive genomic profiling has revolutionized oncology by detecting a wide array of genetic alterations, it has simultaneously introduced a significant clinical challenge in the form of variants of uncertain significance. These genetic changes occupy a middle ground where their impact on cancer progression or treatment response remains entirely unknown, often outnumbering clearly identified pathogenic mutations. Researchers at Hiroshima University developed a practical framework to sift through this mounting uncertainty, aiming to provide clinicians with a reliable method for prioritizing which variants require immediate functional analysis. According to Hiroaki Niitsu, this systematic approach is essential for managing the growing volume of genomic data now integrated into routine cancer care.

The Clinical Catalyst of an Exceptional Remission

The motivation for this genomic study originated from a remarkable clinical case involving a patient who achieved long term remission despite a poor prognosis and multi organ recurrence. This individual exhibited an unexpectedly powerful response to platinum based chemotherapy, a phenomenon that suggested an underlying genetic vulnerability within the tumor that had not been previously identified. By analyzing the patient's genomic profile, the research team focused on a specific BRCA2 variant that had been categorized as a variant of uncertain significance. This case served as a real world proof of concept for the new framework, demonstrating that hidden pathogenic markers can be the decisive factor in explaining extraordinary therapeutic outcomes.

Utilizing Predictive Models to Evaluate Genetic Variations

To test the efficacy of their prioritization framework, the research team analyzed data from over 2,000 genomic tests conducted across 13 institutions in Japan between 2019 and 2025. Out of 526 detected variants in the BRCA1 and BRCA2 genes, the majority were classified as uncertain, representing 153 unique genetic changes. The researchers employed 10 different computational predictors to estimate how these variants might impact protein function or RNA splicing. This bioinformatic screening allowed the team to narrow the field down to 10 high priority variants, including eight missense and two splicing alterations, which warranted intensi...